Sign In
Buy HIMS
$28.01
+0.500 (+1.82%)
At Close: Jun 04, 2026
LOS ANGELES, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behal
Hims & Hers drops on revenue miss
11:23am, Tuesday, 05'th Aug 2025
CNBC's Brandon Gomez joins 'Squawk on the Street' to discuss the latest earnings from Hims & Hers.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
11:20am, Tuesday, 05'th Aug 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options
Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analysts Say
11:11am, Tuesday, 05'th Aug 2025
Shares of Hims & Hers Health Inc HIMS are under pressure Tuesday, after the company reported downbeat second-quarter revenues.
Why Hims & Hers Health Stock Just Dropped
11:07am, Tuesday, 05'th Aug 2025
Hims & Hers Health (HIMS -6.11%), the telehealth company famous for selling Ozempic lookalikes over the internet, is tumbling today, down 6.7% through 10:55 a.m. ET after missing in its second-quarter
Why Did Hims & Hers Stock Crash and Then Recover After Earnings?
11:03am, Tuesday, 05'th Aug 2025
In this video, I will go over Hims & Hers' (HIMS -3.25%) latest earnings report and explain why the stock reacted the way it did. Watch the short video to learn more, consider subscribing, and click t
Hims & Hers falls as declining subscriber base weighs on revenue
10:38am, Tuesday, 05'th Aug 2025
Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment a
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). S
What's Next For HIMS Stock?
09:50am, Tuesday, 05'th Aug 2025
Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong growth but did not meet revenue forecasts. The company disclosed revenue of
Hims & Hers shares fall on mixed Q2 report, light revenue forecast
09:37am, Tuesday, 05'th Aug 2025
Hims & Hers (NYSE:HIMS) shares fell 12% before US markets opened on Tuesday as the company posted mixed results for the second quarter and issued cautious guidance. The company reported revenue of $5
Wall Street sets HIMS' stock price for the next 12 months
09:36am, Tuesday, 05'th Aug 2025
As telehealth company Hims & Hers Health (NYSE: HIMS) navigates a turbulent short-term period following a disappointing Q2 2025 earnings report, some on Wall Street are projecting extended losses for
Class Action Filed Against Hims & Hers Health, Inc. (HIMS) Seeking Recovery for Investors - Contact Levi & Korsinsky
08:45am, Tuesday, 05'th Aug 2025
NEW YORK , Aug. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities law
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of
Hims & Hers: Buy The Core Engine, Not The Headline
08:15am, Tuesday, 05'th Aug 2025
Hims & Hers Health's Q2 revenue miss and decelerating growth triggered a stock drop, but core business ex-GLP-1 remains robust with strong subscriber growth. Profitability is improving, with adjusted
Hims & Hers: Buy The Earnings Dip, Slowly (Rating Downgrade)
07:30am, Tuesday, 05'th Aug 2025
Despite a Q2 revenue miss and cash flow inflection into negative territory, Hims & Hers' long-term growth prospects remain intact due to ongoing platform broadening and international expansion. Manage
